MRNA Vaccine Study
A Study to Evaluate the Efficacy, Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age or Older
SEX AT BIRTH: All
HEALTHY PARTICIPANTS: Yes
Interested in this Study or Have Questions?
Or email the Infectious Disease Clinical Trial Unit
The purpose of this study is to evaluate the efficacy, safety, tolerability, and immunogenicity of a quadrivalent influenza modRNA vaccine (qIRV) encoding HA of 4 seasonally recommended strains (2 A strains and 2 B strains) compared to licensed quadrivalent influenza vaccine (QIV) in healthy adults 18 years of age and older.
Who Can Participate
Healthy participants 18 years and older who are willing and able to comply with all scheduled visits, investigational plan, laboratory tests, lifestyle considerations, and other study procedures may be eligible for this study.